CDEX Files 2006 10K and Schedules Investor Call
ValiMed Makes Market Debut and Company Signs New Investment
Last Update: 8:41 AM ET Feb 5, 2007
TUCSON, Ariz., Feb 05, 2007 (BUSINESS WIRE) -- CDEX Inc. (CEXI
CEXI ) Today, CDEX filed its 10K for fiscal year 2006 reporting, among other things, first shipments of its ValiMed product line through Baxa Corporation, its exclusive distributor in the U.S. and Canada. Sales of ValiMed units have resulted in the highest annual revenue in the Company's history and gross margins continued in excess of 50%.
"Fiscal year 2006 saw the introduction of our first production units of ValiMed into the medical markets, and we expect to ship our first Methamphetamine Detection products into the security markets in 2007," said Tim Shriver, President and CEO. "As the Company has moved from technology development to product implementation, we have looked for opportunities to streamline our operations in product development, sales and marketing, and administrative expenses, and have done so. Significantly, the company closed over $225k of new funding in January, and signed agreements for additional funding to begin in the second quarter of FY 2007."
The Company has scheduled a 45 minute conference call for interested persons for Friday February 9 at 10:00 AM EST to discuss the SEC filings. The call will be limited to the first 50 individuals to call in. A recording of the call will be posted on the Company's web site for the following three weeks for those interested.
Conference Call Details: The moderator will begin accepting calls from participants 10 minutes prior to the start of the call. You will need to identify yourself and state if you are an investor or a member of the general public before being connecting into the conference call.
Dial-In: -------- Local / International: 416-640-3404 North American Toll- Free: 1-866-322-1159 Conference ID: CDEX 10K Conference Call
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc. Malcolm Philips 520-745-5172 mphilips@cdex-inc.com |
